JOHN KIRKWOOD to RNA, Messenger
This is a "connection" page, showing publications JOHN KIRKWOOD has written about RNA, Messenger.
Connection Strength
0.220
-
Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumab. J Immunother Cancer. 2017 08 15; 5(1):67.
Score: 0.091
-
Blood mRNA expression profiling predicts survival in patients treated with tremelimumab. Clin Cancer Res. 2014 Jun 15; 20(12):3310-8.
Score: 0.072
-
Association of TERT promoter mutations with telomerase expression in melanoma. Pigment Cell Melanoma Res. 2016 May; 29(3):391-3.
Score: 0.021
-
Methylation levels of the "long interspersed nucleotide element-1" repetitive sequences predict survival of melanoma patients. J Transl Med. 2011 May 26; 9:78.
Score: 0.015
-
Characterization of amplifiable, circulating RNA in plasma and its potential as a tool for cancer diagnostics. Clin Chem. 2004 Mar; 50(3):564-73.
Score: 0.009
-
Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J Exp Med. 2002 Sep 02; 196(5):619-28.
Score: 0.008
-
Molecular analysis of melanoma precursor lesions. Cell Growth Differ. 1996 Dec; 7(12):1733-40.
Score: 0.005